Enarodustat for anemia in kidney disease patients not on dialysis
Treatments studied
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This trial tests whether starting enarodustat (a pill) at different doses can raise red blood cell levels and treat anemia in people with moderate-to-severe chronic kidney disease who are not yet on dialysis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You weigh between 100 and 220 pounds (45–100 kg).
- You have stage 3–5 chronic kidney disease and are not on dialysis.
- Your hemoglobin (the oxygen-carrying part of blood) is either low (between 7–10 g/dL) and you haven't taken anemia shots in the last 12 weeks, or is between 10–12 g/dL and you have been on anemia shots for at least 8 weeks.
- You must be willing to use birth control if female and able to participate for the full study.
- You do not have certain other health problems like poorly controlled high blood pressure, recent heart attack or stroke, active infections, or a history of cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different doses of pegmolesatide to treat anemia in people with chronic kidney disease who are not on dialysis. It aims to find which dose works better to raise red blood cell levels.
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
This trial tests enarodustat, a pill for anemia, in people with chronic kidney disease who are not on dialysis. It aims to see if it can safely raise hemoglobin levels.
This study tests a daily pill that helps people with chronic kidney disease and anemia make more red blood cells, which may reduce the need for other anemia treatments. It is for patients who are not on dialysis and do not plan to start dialysis or have a kidney transplant within the next six months.
This trial tests a new drug called enarodustat combined with an existing immune-suppressing medicine (CsA) to treat aplastic anemia—a rare blood disorder where your bone marrow doesn't make enough blood cells. The goal is to help your body produce more red blood cells without needing a bone marrow transplant.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
Hear when a new Renal Anemia in Non-dialysis Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.